CoChat

Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study

Open access
Os, Ingrid, Franco, Veronica, Kjeldsen, Sverre E., Manhem, Karin, Devereux, Richard B., Gerdts, Eva, Hille, Darcy A., Lyle, Paulette A., Okin, Peter M., Dahlöf, Björn, Oparil, Suzanne · 2008 · Hypertension
Cited by 68

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Hypertension is a risk factor for cardiovascular disease and outcomes in women. These posthoc analyses from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study evaluated losartan- versus atenolol-based therapy on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and other end points in 4963 women. Fewer events occurred in women versus men. Women in the losartan group had significant reductions in the primary end point (215 [18.2 per 1000 patient-years] versus 261 [22.5 per 1000 patient-years]; hazard ratio [HR]: 0.82 [95% CI: 0.68 to 0.98]; P =0.031), stroke (109 versus 154; HR: 0.71 [95% CI: 0.55 to 0.90]; P =0.005), total mortality (HR: 0.77 [95% CI: 0.63 to 0.95]; P =0.014), and new-onset diabetes (HR: 0.75 [95% CI: 0.59 to 0.94]; P =0.015) versus the atenolol group, with no between-treatment difference for myocardial infarction (HR: 1.02 [95% CI: 0.74 to 1.39]; P =0.925), cardiovascular mortality (HR: 0.86 [95% CI: 0.64 to 1.14]; P =0.282), or hospitalization for heart failure (HR: 0.94 [95% CI: 0.68 to 1.28]; P =0.677). More women in the losartan group required hospitalization for angina (HR: 1.70 [95% CI: 1.16 to 2.51]; P =0.007). Risk reductions for the primary composite end point, stroke, total mortality, and new-onset diabetes were significantly greater with losartan- versus atenolol-based treatment in women with hypertension and left ventricular hypertrophy in the LIFE study. The risk reductions for losartan, along with the tests for the interaction of treatment and gender, indicated that the treatment effect was consistent in men and women for all of the end points tested, with the exception of hospitalization for angina.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hypertensionaha.107.105296

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 68

Metadata

Authors
Os, I., Franco, V., Kjeldsen, S. E., Manhem, K., Devereux, R. B., Gerdts, E., Hille, D. A., Lyle, P. A., Okin, P. M., Dahlöf, B., & Oparil, S.
Venue
Hypertension
Published
2008-04
Volume
51
Issue
4
Pages
1103-1108
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W2131637358
Cited by
68
References
5
FWCI
3.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study. https://app.cochat.ai/papers/10.1161/hypertensionaha.107.105296
The paper
Os, I., Franco, V., Kjeldsen, S. E., Manhem, K., Devereux, R. B., Gerdts, E., Hille, D. A., Lyle, P. A., Okin, P. M., Dahlöf, B., & Oparil, S. (2008). Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension. https://doi.org/10.1161/hypertensionaha.107.105296

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.